Neurocrine Bio. (NBIX) PT Raised to $100 at BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mailGet Alerts NBIX Hot Sheet
Price: $166.05 --0%
Rating Summary:
31 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Rating Summary:
31 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Join SI Premium – FREE
BMO Capital analyst Evan David Seigerman raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $100.00 (from $96.00) while maintaining a Market Perform rating.
You May Also Be Interested In
- Neurocrine Bio. (NBIX) PT Raised to $224 at Guggenheim
- Neurocrine Biosciences Presents New Tardive Dyskinesia Survey Results Showing Fewer Work and School Disruptions with INGREZZA® (valbenazine) Capsules
- Emerson (EMR) PT Raised to $196 at Bernstein SocGen Group
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
